Posted in | News | Nanomaterials | Nanoenergy

Research Grant to Develop Atomically and Molecularly Structured Surfaces

Carnegie Mellon University's Andrew J. Gellman will use a $2 million research grant from the Department of Energy to continue developing atomically and molecularly structured surfaces that will have an enormous impact on the efficiency of catalysts used to create products for the specialty chemical and petroleum industries.

Gellman, head of Carnegie Mellon's Chemical Engineering Department, is leading a research team dedicated to developing new solid surfaces that can be used to select between the "left-handed'' and "right-handed'' versions of complex molecules that appear to be identical but can have vastly different properties.

"We are developing surfaces and chemical reactions that will help a variety of industry sectors control chemical processes to select the best products from a myriad of alternatives,'' said Gellman, who is also director of a new energy consortium created to develop, cleaner, more efficient use of fossil fuels.

Gellman said that in chemical reactions, a chemical reactant is often converted into many different products, in spite of the fact that only one is desired or useful; thus creating significant waste.

"Controlling a reaction to yield only the desired product is one of the key strategies in improving the efficiency and reducing the environmental impact of chemical processes,'' said Gellman.

Gellman's team is tackling the hardest of these challenges, that of selecting between two molecules that differ only in their handedness.

There is significant interest in using biomolecules such as cellulose and sugars as the feedstocks for chemical processes and in biofuels production, according to Gellman "Many of these biomolecules and the products of their reactions come in right-and-left-handed forms and so, the design of catalysts that will control their handedness during chemical reactions is extremely important but also extremely difficult,'' Gellman said.

The work being conducted by Gellman and his collaborators is also highly relevant to the pharmaceutical industry. "By synthesizing or purifying pharmaceuticals so they contain only one-handedness improves pharmaceutical efficacy and can extend the life of some drug patents,'' Gellman said.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.